Want to see BYSI full AI Analyst Report?
BYSI Stock Chart & Stats
$0.66
$0.05(4.46%)
At close: 4:00 PM EDT
$0.66
$0.05(4.46%)
Day’s Range― - ―
52-Week Range$0.57 - $2.44
Previous Close$1.17
Volume9.77K
Average Volume (3M)1.39M
Market Cap
$25.12M
Enterprise Value$65.14
Total Cash (Recent Filing)$6.53M
Total Debt (Recent Filing)$171.00K
Price to Earnings (P/E)―
Beta>-0.01
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,119,820
10 Day Avg. Volume87,387
30 Day Avg. Volume1,385,038
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)-2.05
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Leadership TransitionThe incoming leaders bring capital-markets, finance, governance, and regional pharma experience. Their mandate to advance the lead trial and expand partnerships could improve execution, funding access, and strategic focus over the medium term.
Narrowing LossesThe substantial reduction in annual losses indicates improved cost control compared with earlier years. Although the company remains unprofitable, continued discipline could extend its runway and make future financing more efficient.
Lead Asset DevelopmentA confirmatory Phase 3 program provides a defined path to test the lead candidate in a potentially commercial indication. Successful execution could support regulatory progress, partnerships, and future licensing or royalty revenue.
Bears Say
No Recurring Product RevenueWithout recurring product sales, the business lacks operating revenue to fund research and corporate costs. Its financial outlook therefore remains dependent on clinical success, licensing activity, milestone income, or additional capital.
Persistent Cash BurnOngoing negative operating and free cash flow means the company cannot currently self-fund development. Continued spending on trials and operations will require liquidity management and likely external funding over the medium term.
Negative Equity And Shrinking AssetsNegative equity and a materially smaller asset base signal weak balance-sheet resilience despite low nominal debt. This reduces financial flexibility and increases dependence on financing or successful development outcomes.
Beyondspring News
BYSI FAQ
What was Beyondspring Inc’s price range in the past 12 months?
Beyondspring Inc lowest stock price was $0.56 and its highest was $2.44 in the past 12 months.
What is Beyondspring Inc’s market cap?
Beyondspring Inc’s market cap is $25.12M.
When is Beyondspring Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Beyondspring Inc’s earnings last quarter?
Currently, no data Available
Is Beyondspring Inc overvalued?
According to Wall Street analysts Beyondspring Inc’s price is currently Overvalued.
Does Beyondspring Inc pay dividends?
Beyondspring Inc does not currently pay dividends.
What is Beyondspring Inc’s EPS estimate?
Beyondspring Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beyondspring Inc have?
Beyondspring Inc has 41,119,820 shares outstanding.
What happened to Beyondspring Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beyondspring Inc?
Currently, no hedge funds are holding shares in BYSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beyondspring Inc
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Technical Analysis
Ownership Overview
10.96% Insiders
2.19% Mutual Funds
9.31% Other Institutional Investors
75.54% Public Companies and
Individual Investors